Hangzhou Tangji Medical Techonology Co., LtdN39.E79Tangji Medical Technology
Since being founded in Hangzhou, China in 2016, Tongee's vision is to develop new ways to treat metabolic disease. Our mission is to relieve patients who suffer from metabolic diseases around the world from their pain and help them regain health and happiness. We have developed multiple new medical technologies for metabolic diseases such as obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease. The Gastric Bypass Stent System, an innovative Class III medical device pioneered by Tongee, has been officially approved for marketing in multiple countries both domestically and internationally, serving a wider range of minimally invasive treatment options for patients with metabolic diseases.
There remains substantial unmet clinical needs in the prevention and treatment of metabolic diseases. As a national high-tech enterprise in China, Tongee is committed to building an innovative platform for interventional gastrointestinal therapies and related medical equipment, disease management and solutions. In addition to the Gastric Bypass Stent System, Tongee is also developing a full product line for weight loss and metabolic disease treatment, including Intragastric Balloon, creating a comprehensive product matrix covering "diverse needs and all intervention stages".
